Next Article in Journal
Annexin A1 Regulates Retinal Gliosis in Diabetic Retinopathy
Previous Article in Journal
Untangling the Microscopic World of Organelles, Cells, Tissues, and Organs: A Focus on the Dysfunctional Golgi Apparatus in Disease Research
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Building Implantable Human Liver Tissue from Pluripotent Stem Cells †

Centre for Regenerative Medicine, University of Edinburgh, Edinburgh EH16 4UU, UK
Presented at Cells, Cells and Nothing but Cells: Discoveries, Challenges and Directions, 6–8 March 2023; Available online: https://cells2023.sciforum.net/.
Biol. Life Sci. Forum 2023, 21(1), 16; https://doi.org/10.3390/blsf2023021016
Published: 21 March 2023

Abstract

:
Liver disease is an escalating global health issue. While liver transplantation is an effective mode of therapy, patient mortality has increased due to the shortage of donor organs. Therefore, developing renewable sources of human liver tissue is attractive. Pluripotent stem cell-derived liver tissue represents a potential alternative to cadaver derived hepatocytes and whole organ transplant. At present, two-dimensional differentiation procedures deliver tissue lacking certain functions and phenotypic instability. Efforts to overcome these limiting factors have led to the building of three-dimensional (3D) cellular aggregates. Although enabling for the field, their widespread application and adoption is limited due to the reliance on variable biological components. Our study focus on developing 3D liver tissue under defined conditions. We demonstrate that 3D derived tissue can be generated at scale and implanted underneath the skin of mice. Excitingly, implanted human tissue provides support to mice with metabolic liver disease. This includes immunocompetent recipients. In addition to their clinical application, in vitro generated 3D tissues have important roles to perform in developing safe and efficacious medicines to treat human diseases. We demonstrate that stem cell derived 3D liver tissue exhibits liver cell phenotype for over one year in culture, providing an attractive resource for long-term disease modelling and screening studies. In conclusion, stem cell derived liver tissue has great potential for in vitro and in vivo endeavours. Our most recent advances will be presented at the meeting.

Funding

UK Regenerative Medicine Platform (MRC MR/L022974/1), Chief Scientist’s Office (TCS/16/37).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Conflicts of Interest

David Hay is a founder, director and shareholder in Stimuliver ApS and Stemnovate Limited.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hay, D. Building Implantable Human Liver Tissue from Pluripotent Stem Cells. Biol. Life Sci. Forum 2023, 21, 16. https://doi.org/10.3390/blsf2023021016

AMA Style

Hay D. Building Implantable Human Liver Tissue from Pluripotent Stem Cells. Biology and Life Sciences Forum. 2023; 21(1):16. https://doi.org/10.3390/blsf2023021016

Chicago/Turabian Style

Hay, David. 2023. "Building Implantable Human Liver Tissue from Pluripotent Stem Cells" Biology and Life Sciences Forum 21, no. 1: 16. https://doi.org/10.3390/blsf2023021016

APA Style

Hay, D. (2023). Building Implantable Human Liver Tissue from Pluripotent Stem Cells. Biology and Life Sciences Forum, 21(1), 16. https://doi.org/10.3390/blsf2023021016

Article Metrics

Back to TopTop